Results 131 to 140 of about 2,496 (195)

The Impact of Novel Medications for Obesity on Weight Stigma and Societal Attitudes: A Narrative Review. [PDF]

Curr Obes Rep
Heitmann BL.
europepmc   +1 more source

Receptor interaction profiles of 4-alkoxy-2,6-dimethoxyphenethylamines (Ψ derivatives) and related amphetamines. [PDF]

Front Pharmacol
Kolaczynska KE, Trachsel D, Hoener MC, Liechti ME, Luethi D.   +4 more
europepmc   +1 more source

Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats. [PDF]

Biochem Pharmacol
Chandler CM, Nickell JR, George Wilson A, Culver JP, Crooks PA, Bardo MT, Dwoskin LP.   +6 more
europepmc   +1 more source

Social network analysis for medical narcotics in South Korea: focusing on patients and healthcare organizations. [PDF]

BMC Health Serv Res
Kim SY, Cho NW.
europepmc   +1 more source

The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists. [PDF]

Am J Psychiatry
Imperio CG, Levin FR, Martinez D.
europepmc   +1 more source

Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity.

Endocr Rev
van Santen HM, Müller HL.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mazindol for Nocturnal Enuresis

British Journal of Urology, 1984
Summary— Sixteen adult enuretics who had failed to respond to simple conventional treatment of their symptoms have been investigated and treated with mazindol. Sixty‐three per cent have been made dry and improvement achieved in a further 31%.
R C, Tiptaft, C R, Woodhouse, D F, Badenoch   +2 more
openaire   +2 more sources

Analogs of the Anorexic Mazindol

Journal of Pharmaceutical Sciences, 1975
Mazindol, 5-(p-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol, has been shown to be an effective anorexic. To explore the structure-activity relationships, several 1-ethyl-3-substituted-4-aryl-4-hydroxyindeno[1,2-c]pyrazoles were prepared and subjected to various animal screens.
T L, Lemke, L A, Cates, M, Steenberg, Y M, Cho   +3 more
openaire   +2 more sources

Mazindol in the treatment of narcolepsy

Acta Neurologica Scandinavica, 2009
Thirty-four subjects with the narcoleptic syndrome were treated with mazindol 3--8 mg daily for 1 year. Treatment cuased a sustained improvement in narcolepsy, but had no effect on cataplexy or sleep paralysis. The response to mazindol was excellent in six subjects, good in 14, moderate in 12 and poor in two.
J D, Parkes, M, Schachter
openaire   +2 more sources